The ThinWorks Expert Support Team will be more than happy to answer your questions
Dini L, Autuori F, Lentini A, Oliverio S, Piacentini M
Institutional research settings that track NAD+ levels and methylnicotinamide excretion often find individual dose-response variability of 3040%, meaning the 'right' dose for one subject may be subtherapeutic or excessive for another
Self-sourced "research peptides" from unregulated sources carry significant quality and safety risks, physician oversight is essential
Additionally, not all patients may benefit from exhaustive diagnostic workups, and an over-reliance on patch testing may lead to deferred treatment, poorer symptom control, and worsen patient outcomes [5,6,7,8,9,10,11,12]
2013;8(9) doi: 10.1371/journal.pone.0074223